Quoin Pharmaceuticals (QNRX) Q3 2024 earnings summary

Executive summary

• Focused on developing therapies for rare and orphan diseases, with lead asset QRX003 in late-stage clinical trials for Netherton Syndrome and expansion into international sites in Saudi Arabia, the UK, and New Zealand.

• Initiated first-ever clinical study for QRX003 in Peeling Skin Syndrome, expanding pipeline indications.

• Entered a research agreement with University College Cork for novel rapamycin formulations targeting rare diseases.

• Management team made significant insider share purchases, reflecting confidence in long-term growth.

Financial highlights

• Net loss of $6.7 million for the nine months ended September 30, 2024, compared to $6.6 million for the same period in 2023.

• Cash, cash equivalents, and investments totaled $10.3 million as of September 30, 2024, expected to fund operations into late 2025.

• Operating expenses totaled $7.1 million for the nine months ended September 30, 2024, with $4.6 million in general and administrative and $2.5 million in research and development.

• Net cash used in operating activities was $5.6 million for the nine months ended September 30, 2024.

• Loss per ADS for Q3 2024 was $0.47, compared to $1.95 in Q3 2023.

Outlook and guidance

• Sufficient liquidity to fund operations for at least one year from the financial statement issuance date, with cash expected to last into late 2025.

• Additional financing will be required to complete development and commercialization of product candidates.

• Plans to expand clinical trial sites internationally and advance pipeline assets, including evaluating M&A opportunities.